Circulating Tumor Cell Detection for Therapeutic and Prognostic Roles in Breast Cancer
ABSTRACT Background Circulating tumor cells (CTCs) are pivotal liquid biopsy (LB) biomarkers for breast cancer (BC), offering non‐invasive insights into tumor progression and metastasis. Despite their clinical promise, CTC detection remains technically challenging due to their extreme rarity in peri...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.70902 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849330289813225472 |
|---|---|
| author | Saiying Ma Xiaojia Wang Peter Ping Lin Lei Lei |
| author_facet | Saiying Ma Xiaojia Wang Peter Ping Lin Lei Lei |
| author_sort | Saiying Ma |
| collection | DOAJ |
| description | ABSTRACT Background Circulating tumor cells (CTCs) are pivotal liquid biopsy (LB) biomarkers for breast cancer (BC), offering non‐invasive insights into tumor progression and metastasis. Despite their clinical promise, CTC detection remains technically challenging due to their extreme rarity in peripheral blood. Methods This review systematically evaluates CTC detection methodologies, including immunoaffinity‐based approaches and biophysical techniques, which exhibit inherent trade‐offs in sensitivity, specificity, and compatibility with downstream analyses. Furthermore, post‐isolation molecular characterization methods spanning genomic, transcriptomic, and proteomic analyses are also critically assessed. Key Findings CTC molecular profiling holds significant clinical relevance, enabling early diagnosis, prognostic stratification, and real‐time monitoring of therapeutic response. Baseline CTC counts or quantitative/phenotypic changes during treatment inform therapeutic decision‐making, predict drug resistance, and correlate with recurrence risk and metastatic progression. Conclusion Multimodal analysis integrating CTC morphology, surface markers, and molecular alterations advances precision therapy. However, standardization of detection platforms and clinical validation of CTC‐guided protocols remain essential. |
| format | Article |
| id | doaj-art-4ee0a4a335e2404abb7707df5c52385c |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-4ee0a4a335e2404abb7707df5c52385c2025-08-20T03:46:58ZengWileyCancer Medicine2045-76342025-06-011411n/an/a10.1002/cam4.70902Circulating Tumor Cell Detection for Therapeutic and Prognostic Roles in Breast CancerSaiying Ma0Xiaojia Wang1Peter Ping Lin2Lei Lei3Zhejiang Chinese Medical University Hangzhou ChinaZhejiang Cancer Hospital Hangzhou ChinaCytelligen San Diego California USAZhejiang Cancer Hospital Hangzhou ChinaABSTRACT Background Circulating tumor cells (CTCs) are pivotal liquid biopsy (LB) biomarkers for breast cancer (BC), offering non‐invasive insights into tumor progression and metastasis. Despite their clinical promise, CTC detection remains technically challenging due to their extreme rarity in peripheral blood. Methods This review systematically evaluates CTC detection methodologies, including immunoaffinity‐based approaches and biophysical techniques, which exhibit inherent trade‐offs in sensitivity, specificity, and compatibility with downstream analyses. Furthermore, post‐isolation molecular characterization methods spanning genomic, transcriptomic, and proteomic analyses are also critically assessed. Key Findings CTC molecular profiling holds significant clinical relevance, enabling early diagnosis, prognostic stratification, and real‐time monitoring of therapeutic response. Baseline CTC counts or quantitative/phenotypic changes during treatment inform therapeutic decision‐making, predict drug resistance, and correlate with recurrence risk and metastatic progression. Conclusion Multimodal analysis integrating CTC morphology, surface markers, and molecular alterations advances precision therapy. However, standardization of detection platforms and clinical validation of CTC‐guided protocols remain essential.https://doi.org/10.1002/cam4.70902breast cancercirculating tumor cellcirculating tumor endothelial celldetecting technologyliquid biopsy |
| spellingShingle | Saiying Ma Xiaojia Wang Peter Ping Lin Lei Lei Circulating Tumor Cell Detection for Therapeutic and Prognostic Roles in Breast Cancer Cancer Medicine breast cancer circulating tumor cell circulating tumor endothelial cell detecting technology liquid biopsy |
| title | Circulating Tumor Cell Detection for Therapeutic and Prognostic Roles in Breast Cancer |
| title_full | Circulating Tumor Cell Detection for Therapeutic and Prognostic Roles in Breast Cancer |
| title_fullStr | Circulating Tumor Cell Detection for Therapeutic and Prognostic Roles in Breast Cancer |
| title_full_unstemmed | Circulating Tumor Cell Detection for Therapeutic and Prognostic Roles in Breast Cancer |
| title_short | Circulating Tumor Cell Detection for Therapeutic and Prognostic Roles in Breast Cancer |
| title_sort | circulating tumor cell detection for therapeutic and prognostic roles in breast cancer |
| topic | breast cancer circulating tumor cell circulating tumor endothelial cell detecting technology liquid biopsy |
| url | https://doi.org/10.1002/cam4.70902 |
| work_keys_str_mv | AT saiyingma circulatingtumorcelldetectionfortherapeuticandprognosticrolesinbreastcancer AT xiaojiawang circulatingtumorcelldetectionfortherapeuticandprognosticrolesinbreastcancer AT peterpinglin circulatingtumorcelldetectionfortherapeuticandprognosticrolesinbreastcancer AT leilei circulatingtumorcelldetectionfortherapeuticandprognosticrolesinbreastcancer |